Universities and research institutions in Berlin

ELANA® Heart Bypass Solution shows promising preliminary results in first-in-human trials

Retrieved on: 
Saturday, October 8, 2022
Excimer laser, News, Time, Stroke, FIH, Infection, Universities and research institutions in Berlin, MACE, Patient, Major adverse cardiovascular events, Cardiac catheterization, Mortality, Technology, Van Tulleken brothers, Coronary artery bypass surgery, Goal, CABG, DRS, Blood, CEO, Safety, Brain, ELANA, Surgeon, Human, MILAN, Pharmaceutical industry, Medical imaging

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

Key Points: 
  • Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
  • MILAN, Oct. 8, 2022 /PRNewswire/ -- The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass Solution have been unveiled today and look promising.
  • This news marks an important landmark for the ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis) Heart Bypass Solution and its developer, AMT Medical.
  • "A sutureless coronary anastomosis device like the ELANA Heart Bypass Solution could effectively facilitate minimally invasive CABG," he said.

ELANA® Heart Bypass Solution shows promising preliminary results in first-in-human trials

Retrieved on: 
Saturday, October 8, 2022
Excimer laser, News, Time, Stroke, FIH, Infection, Universities and research institutions in Berlin, MACE, Patient, Major adverse cardiovascular events, Cardiac catheterization, Mortality, Technology, Van Tulleken brothers, Coronary artery bypass surgery, Goal, CABG, DRS, Blood, CEO, Safety, Brain, ELANA, Surgeon, Human, MILAN, Pharmaceutical industry, Medical imaging

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

Key Points: 
  • Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
  • ELANA Heart Bypass Solution shown to be safe and feasible in humans, with all candidates free of Major Adverse Cardiovascular Events (MACE) at post-operative day 30.
  • MILAN, Oct. 8, 2022 /PRNewswire/ -- The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass Solution have been unveiled today and look promising.
  • This news marks an important landmark for the ELANA (Excimer Laser Assisted Non-Occlusive Anastomosis) Heart Bypass Solution and its developer, AMT Medical.

The U.S. and Israeli Governments announce a Call for Proposals to fund Advanced Homeland Security Technologies through the BIRD Foundation

Retrieved on: 
Wednesday, February 23, 2022
Risk, System, Program, Board, Intellectual property, Public, Communication, TEL, Privacy Office of the U.S. Department of Homeland Security, Robotics, Personal protective equipment, U.S. Department of Defense Strategy for Operating in Cyberspace, Biometrics, Universities and research institutions in Berlin, BIRD Foundation, Homeland security, United States Customs and Border Protection Authorization Act, Industry, HLS, Control, Estonian Academy of Security Sciences, Maritime security, Adequate Public Facilities Ordinance, Foundation, DHS Science and Technology Directorate, First responder, BIRD, R, Marketing, Executive summary, Unmanned aerial vehicle, Command, Identification, DHS, Solution, Research, Board of directors, Department, Online gambling, Renewable energy, Publishing

TEL AVIV, Israel, Feb. 23, 2022 /PRNewswire/ -- The Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation has issued a Call for Proposals to U.S. and Israeli entities in the Homeland Security sector to submit joint proposals for the development of advanced Homeland Security technologies.

Key Points: 
  • TEL AVIV, Israel, Feb. 23, 2022 /PRNewswire/ -- The Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation has issued a Call for Proposals to U.S. and Israeli entities in the Homeland Security sector to submit joint proposals for the development of advanced Homeland Security technologies.
  • The BIRD HLS program, funded by the U.S. Department of Homeland Security and the Israel Ministry of Public Security, has been providing grants since 2016 to support joint U.S.-Israeli research and development projects.
  • The program is managed by the BIRD Foundation and addresses needs and innovation areas defined by both countries.
  • BIRD HLS is directed towards U.S. and Israeli companies that develop Homeland Security products and solutions, and towards entities in other sectors that develop technologies that may be suitable for this sector.

Pi-Cardia ShortCut(TM) Device Successfully Treats First Patients in Europe

Retrieved on: 
Monday, December 20, 2021
Calcification, Clinical trial, Physician, Hemodynamics, Aortic stenosis, Growth, Percutaneous aortic valve replacement, Risk, Patient, Shortcut, Universities and research institutions in Berlin, ISRAEL, Heart, TAVR, Medical device

"We were able to successfully treat three patients with degenerated valves who were at risk of coronary obstruction after TAVR with the ShortCut(TM) device," said Prof. Kempfert.

Key Points: 
  • "We were able to successfully treat three patients with degenerated valves who were at risk of coronary obstruction after TAVR with the ShortCut(TM) device," said Prof. Kempfert.
  • ShortCut(TM) is part of Pi-Cardia's product portfolio, which also includes the Leaflex(TM) device - a standalone, non-implant-based treatment for patients with aortic stenosis.
  • "As the number of patients with aortic stenosis continues to grow, both Shortcut(TM) and Leaflex(TM) may offer important new treatment options for both physicians and patients."
  • The Leaflex(TM) device is designed to be a cost-effective, durable standalone treatment for patients with calcified aortic stenosis.